Your shopping cart is currently empty

Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098μM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8μM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $31 | In Stock | In Stock | |
| 10 mg | $47 | In Stock | In Stock | |
| 25 mg | $82 | In Stock | In Stock | |
| 50 mg | $115 | In Stock | In Stock | |
| 100 mg | $162 | - | In Stock | |
| 500 mg | $397 | - | In Stock | |
| 1 g | $593 | - | In Stock | |
| 5 g | $1,250 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $35 | In Stock | In Stock |
| Description | Safinamide (FCE-26743) is a reversible and selective monoamine oxidase B (IC50 0.098μM) inhibitor, reducing the degradation of dopamine, and a glutamate release inhibitor (IC50 8μM). It also inhibits dopamine reuptake. Safinamide also blocks sodium and calcium channels. Potential additional uses of Safinamide might be Parkinson's disease, restless leg syndrome and epilepsy. |
| Targets&IC50 | MAO-A:580 μM, MAO-B:98 nM |
| In vitro | Safinamide (1–300 µM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner. When the holding potential is depolarized to -53 mV, the inhibitory effect of safinamide with a lower IC50 value (8 µM) in rat cortical neurons [1]. |
| In vivo | Daily intraperitoneal injections of Safinamide 1mg/kg were administered for 14 days and the treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice .Safinamide (intraperitoneal injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo [2]. |
| Synonyms | FCE-26743, FCE26743, FCE 26743, EMD-1195686, EMD1195686, EMD 1195686 |
| Molecular Weight | 302.34 |
| Formula | C17H19FN2O2 |
| Cas No. | 133865-89-1 |
| Smiles | O(CC1=CC(F)=CC=C1)C2=CC=C(CN[C@H](C(N)=O)C)C=C2 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (165.38 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.